Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-19T00:55:17.171Z Has data issue: false hasContentIssue false

72 Why TP53 expression varies in lymphoma: Insights from a Bayesian meta-analysis

Published online by Cambridge University Press:  08 May 2026

Aisha Al-Khinji
Affiliation:
Qatar University
Muna Yusuf
Affiliation:
College of Medicine, Qatar University
Noof Al-Thani
Affiliation:
College of Medicine, Qatar University
Hadeel Al Ashwal
Affiliation:
College of Art and Sciences, Qatar University
Abdulatif Al Hor
Affiliation:
College of Medicine, Qatar University
Hissa alkuwari
Affiliation:
College of Medicine, Qatar University
Aida Habib
Affiliation:
College of Medicine, Qatar University
Dhafer Malouche
Affiliation:
College of Art and Sciences, Qatar University
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Objectives/Goals: To quantify between-study heterogeneity in TP53 expression across DLBCL studies using frequentist and Bayesian meta-analytic frameworks; estimate the association between TP53 status and cell-of-origin (GCB vs. non-GCB); and identify methodological and biological sources of variation, using study-level data. Methods/Study Population: Four retrospective study-level datasets (n=457) from France, Canada, Brazil, and the USA were included. TP53 status was primarily assessed by immunohistochemistry (IHC) with study-specific thresholds (20–50% positive cells). Cell-of-origin classification followed the Hans or Choi algorithms as reported by each study. We fit frequentist random effects models with REML (R metafor) and Bayesian hierarchical models (R rstan) Results/Anticipated Results: Frequentist random effects meta-analysis indicated moderate-to-high heterogeneity (I² = 66.7%, p = 0.038) and a pooled odds ratio for GCB among TP53-positive vs. TP53-negative cases of 0.953 (95% CI: 0.682–1.330). The Bayesian hierarchical model estimated P(GCB | TP53+) with a posterior mean of 0.71 (95% CrI: 0.38–0.93); study-level posterior means ranged from 0.37 to 0.53. Both approaches confirm substantial between-study variation attributable to methodological factors (IHC thresholds, COO algorithms) and biological differences Discussion/Significance of Impact: This analysis clarifies the heterogeneity of TP53 expression in lymphoma and shows how methodological and biological variability influence results. Bayesian modeling enhances reliability in small, heterogeneous biomarker syntheses, supporting standardization of TP53 assessment and improving reproducibility in DLBCL.

Information

Type
AI and Data Science
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2026. The Association for Clinical and Translational Science